All In Biotech

Drug Trial Radar · NCT03781219

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

A Phase I, Single Arm, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Preliminary Efficacy of HL-085 Plus Vemurafenib in Patients With BRAF V600 Mutant Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: May 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Jul 1, 2018

Primary completion

Dec 1, 2023

Study completion Dec 1, 2023

Sponsor

Lead sponsor
Shanghai Kechow Pharma, Inc.Industry
Sponsor type
Industry
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetics and efficacy in patients with BRAF V600 mutant advanced solid tumor by HL-085 plus Vemurafenib treatment.

Conditions

  • Solid Tumor

Interventions

  • HL-085Drug

    HL-085 ( Capsule) is one MEK inhibitor.

  • VemurafenibDrug

    Vemurafenib ( Tablet) is BRAF inhibitor,

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse EventsTime frame: up to 12 mouths

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Oncology Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Henan Province Oncology Hospital

    Zhengzhou, Henan, China · Recruiting

  • First Affiliated Hospital, Medicine School of Zhejiang University

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.